Review of Mobile Devices and Health by Ida Sim in the NEJM
mHealth Insight
SEPTEMBER 6, 2019
Simultaneously, these biomarkers must be of sufficient direct value to patients to justify their participation in the data-collection effort. Greater investment in the science of digital biomarkers is needed to evaluate the value of mobile health data for clinical use. None of this is easy. billion in investments in 2018.
48 
Let's personalize your content